- Home
- CRSP
as 07-26-2024 4:00pm EST
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
| Founded: | N/A | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 4.9B | IPO Year: | 2016 |
| Target Price: | $80.29 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.55 - $91.10 | Next Earning Date: | 08-05-2024 |
| Revenue: | $271,710,000 | Revenue Growth: | 171.01% |
| Revenue Growth (this year): | -82.64% | Revenue Growth (next year): | 429.61% |
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bruno Julianne | CRSP | Chief Operating Officer | Jun 20 '24 | Sell | $56.09 | 3,366 | $188,798.94 | 6,745 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Apr 15 '24 | Sell | $59.88 | 18,378 | $1,100,509.56 | 209,326 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Apr 15 '24 | Sell | $60.40 | 1,204 | $72,721.96 | 208,122 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 15 '24 | Sell | $71.97 | 10,613 | $763,810.18 | 217,509 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 15 '24 | Sell | $73.06 | 9,387 | $685,817.97 | 208,122 | SEC Form 4 |
| Prasad Raju | CRSP | Chief Financial Officer | Mar 14 '24 | Sell | $72.69 | 3,524 | $256,159.56 | 6,476 | SEC Form 4 |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Mar 10 '24 | Sell | $78.26 | 2,801 | $219,206.26 | 60,070 | SEC Form 4 |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Mar 10 '24 | Sell | $74.44 | 1,146 | $85,308.24 | 61,174 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 10 '24 | Sell | $78.26 | 9,802 | $767,104.52 | 203,705 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Mar 10 '24 | Sell | $74.44 | 4,583 | $341,158.52 | 208,122 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 18 '24 | Sell | $79.67 | 6,370 | $507,497.90 | 194,257 | SEC Form 4 |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Feb 18 '24 | Sell | $79.67 | 1,913 | $152,408.71 | 57,371 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 15 '24 | Sell | $79.94 | 12,949 | $1,035,089.97 | 194,428 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 15 '24 | Sell | $81.04 | 5,951 | $482,256.54 | 188,477 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Feb 15 '24 | Sell | $81.66 | 1,100 | $89,830.95 | 187,377 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 29 '24 | Sell | $60.50 | 49,300 | $2,982,802.83 | 188,077 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 29 '24 | Sell | $61.10 | 700 | $42,769.86 | 187,377 | SEC Form 4 |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Jan 16 '24 | Sell | $62.50 | 20,000 | $1,250,058.00 | 187,377 | SEC Form 4 |
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
CRISPR Therapeutics Nears 52-Week Low. Time to Buy?
Zacks
3 days ago
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know
Zacks
3 days ago
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
Motley Fool
7 days ago
3 Monster Stocks in the Making to Buy Right Now
Simply Wall St.
9 days ago
Institutional investors must be pleased after a 8.9% gain last week that adds to CRISPR Therapeutics AG's (NASDAQ:CRSP) one-year returns
Zacks
10 days ago
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
Yahoo Finance Video
10 days ago
Dow, S&P 500 rally on strong retail data, gold reaches record high: Yahoo Finance
Motley Fool
11 days ago
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Compare CRSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.